Phaseline

Companies › SK Bioscience

SK Bioscience: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 2 Phase 1, 2 Phase 3; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NBP608 (Mid Potency)
Live attenuated varicella virus vaccine (Oka/SK strain)
–Phase 3Varicella (Chickenpox)Feb 2027
GBP511
Broadly protective sarbecovirus vaccine
–Phase 1Healthy ParticipantsDec 2026
GBP511 + CAS-1
Broadly protective sarbecovirus vaccine with adjuvant
–Phase 1Healthy ParticipantsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07280858GBP511Phase 1Healthy ParticipantsInfectious diseaseDec 2026
NCT07280858GBP511 + CAS-1Phase 1Healthy ParticipantsInfectious diseaseDec 2026
NCT07415252NBP608 (Mid Potency)Phase 3Varicella (Chickenpox)Infectious diseaseFeb 2027
NCT07415252NBP608 (Mid Potency)Phase 3Varicella (Chickenpox)Infectious diseaseFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Inventprise LimmaTech Biologics Sinovac Life Sciences Bharat Biotech International Immorna Biotherapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.